1. Home
  2. ACON vs IMNN Comparison

ACON vs IMNN Comparison

Compare ACON & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclarion Inc.

ACON

Aclarion Inc.

HOLD

Current Price

$3.11

Market Cap

7.7M

Sector

Technology

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.90

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACON
IMNN
Founded
2008
1982
Country
United States
United States
Employees
11
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
ACON
IMNN
Price
$3.11
$1.90
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$7.00
$10.00
AVG Volume (30 Days)
56.8K
49.1K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$87.22
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.34
$0.48
52 Week High
$12.03
$9.32

Technical Indicators

Market Signals
Indicator
ACON
IMNN
Relative Strength Index (RSI) 50.80 42.38
Support Level $2.98 N/A
Resistance Level $3.54 $2.50
Average True Range (ATR) 0.20 0.15
MACD 0.01 0.03
Stochastic Oscillator 54.02 46.67

Price Performance

Historical Comparison
ACON
IMNN

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: